STABILITY INDICATING RP-HPLC-PDA METHOD FOR DETERMINATION OF ABIRATERONE ACETATE AND CHARACTERIZATION OF ITS BASE CATALYZED DEGRADATION PRODUCT BY LC-MS
Objective: The present work describes stability indicating (SI) RP-HPLC-PDA method for determination of abiraterone acetate (ABA) and characterization of its base catalyzed degradation product by LC-MS.
Methods: The separation was achieved by using column Kromasil C18 (250 mm Ã— 4.6 mm, 4.0 Âµ) using acetonitrile (ACN): ammonium acetate buffer 10 mM, pH adjusted to 3.5 with acetic acid (AA) in the ratio of 10:90 % v/v as eluent. The Mobile phase flow rate was 0.6 ml/min and data integration was achieved at 235 nm.
Results: The retention time of ABA was 5.4Â±0.01 min. Linearity was found to be in the range of 5â€“30 Î¼g/ml. The limit of detection and quantitation were 0.25 Î¼g/ml and 0.75 Î¼g/ml respectively, and percentage recovery of ABA was found to be 99.52 to 100.13 %. Mass spectral data of base degraded product of ABA shows a prominent molecular ion peak at m/z-391.5. Major fragmentation leads to formation of 10â€“Methyl 2,3,4,7,8,9,10,11,12,13,14,15-dodecanhydro-1H cyclopenta (Î±)phenanthren-3-ol as a degradant (D2) at m/z-257.81, due to corresponding loss of C8H12ON. All the analytical validation parameters were determined and found in the limit as per ICH guidelines.
Conclusion: The results of the various validation studies showed that the LC method is fast, specific, accurate, reproducible, possessed significant linearity and precision. The drug was found to be stable under all the stress conditions except basic stress. Thus developed method reported first time is novel with a very short run time of 6 min.
2. Gurav SD, Ranindra P, Junaid F, Hohd Z, Shriram R, Ramesh M. Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC-MS/MS-ESI: application to a pharmacokinetic study. Biomed Chromatogr 2012;26:761-8.
3. ICH guidelines for the stability of new drug substances and products. Q1A(R2) ICH, Geneva; 2005. p. 1-13.
4. ICH guidelines for validation of analytical procedures: text and methodology. Q2(R1) ICH, Geneva; 2005. p. 1-14.
5. Mandrupkar SN, Mulgund SV, Nagras MA. Development of validated stability indicating RP-HPLC method for estimation of acenocoumarol in bulk and tablet dosage form. Int J Pharm Sci Rev Res 2012;2:101-6.
6. Dong MW. Modern HPLC for practicing scientist. John Wiley and Sons Inc. Publication; 2006. p. 1-13, 193-221.
7. Boccardi G, Baertschi SW. Pharmaceutical stress testing--predicting drug degradation. Taylor and Francis, New York; 2005. p. 220.
8. Alsante KM, Hatajik TD, Lohr LL. Handbook of isolation and characterization of impurities in pharmaceutical. Academics Press: New York; 2003. p. 380.
9. Ceresole R, Rosasco MA, Forastieri CC, Segall AI. HPLC determination of Acenocoumarol and its major thermal degradation product. J Liq Chromatogr Relat Technol 2008;31:179-87.
10. Kollroser M, Schober C. Determination of coumarin-type anticoagulants in human plasma by HPLC-electrospray ionization tandem mass spectrometry with an ion trap detector. Clin Chem 2002;48:84-91.
11. Gupta A, Rawat S. Method development and hydrolytic degradation study of Doxofylline by RP HPLC and LCâ€“MS/MS. Asian J Pharm Anal 2011;1:29-33.